Benzinga · Aug 6, 2026
NA
NASDAQ · NAUT
Nautilus Biotechnology, Inc.
Healthcare · Biotechnology
$0.90
Down-$0.01 (-1.59%)
Updated Sep 7, 2026, 10:51 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 250.72M
- P/E ratio
- -3.99
- Dividend yield
- 0.00%
- 52-week range
- $0.84 – $4.31
- Volume
- 579.44K
- Avg. volume
- 507.75K
Price performance
NAUT price history
1M range · 20 trading sessions · Daily adjusted prices
NAUT closed at $0.90 after 20 trading sessions, up 4.61% for the selected period.
- Last close
- $0.90
- Period change
- +4.61%
- Period low
- $0.85
- Period high
- $0.97
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $0.9077 | $0.9498 | $0.89 | $0.9049 | 579.44K |
| Sep 3, 2026 | $0.9799 | $0.98 | $0.895 | $0.9195 | 795.84K |
| Sep 2, 2026 | $0.9414 | $0.99 | $0.9201 | $0.9618 | 836.13K |
| Sep 1, 2026 | $0.9609 | $0.972 | $0.9149 | $0.9265 | 570.99K |
| Aug 31, 2026 | $0.90 | $0.98 | $0.89 | $0.9724 | 785.28K |
| Aug 28, 2026 | $0.90 | $0.9199 | $0.8715 | $0.8857 | 489.27K |
| Aug 27, 2026 | $0.95 | $0.9847 | $0.90 | $0.9041 | 522.57K |
| Aug 26, 2026 | $0.9223 | $0.95 | $0.91 | $0.9374 | 864.19K |
| Aug 25, 2026 | $0.89 | $0.9176 | $0.8606 | $0.8813 | 491.81K |
| Aug 24, 2026 | $0.98 | $0.98 | $0.8617 | $0.8753 | 610.79K |
| Aug 21, 2026 | $0.92 | $0.9782 | $0.89 | $0.9545 | 852.44K |
| Aug 20, 2026 | $0.8901 | $0.93 | $0.8756 | $0.9023 | 496.16K |
| Aug 19, 2026 | $0.8846 | $0.9199 | $0.87 | $0.9015 | 515.74K |
| Aug 18, 2026 | $0.8805 | $0.8853 | $0.8448 | $0.8518 | 487.32K |
| Aug 17, 2026 | $0.88 | $0.91 | $0.8602 | $0.8805 | 487.16K |
| Aug 14, 2026 | $0.90 | $0.91 | $0.86 | $0.892 | 630.28K |
| Aug 13, 2026 | $0.9117 | $0.9236 | $0.8819 | $0.89 | 498.11K |
| Aug 12, 2026 | $0.8906 | $0.9151 | $0.8751 | $0.8997 | 608.53K |
| Aug 11, 2026 | $0.8882 | $0.9258 | $0.865 | $0.8908 | 328.14K |
| Aug 10, 2026 | $0.91 | $0.97 | $0.86 | $0.865 | 823.19K |
Latest NAUT news
The latest Smart Investors Daily articles mentioning NAUT.
Stock researchCompany · Overview
NAUT research
Overview
Company profile and research snapshot.
Company profile
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 27, 2026 | Guggenheim | Buy | — |
| Dec 5, 2024 | Goldman Sachs | Sell | — |
| Jun 27, 2024 | Guggenheim | Buy | — |
| Aug 3, 2023 | Morgan Stanley | Equal-Weight | — |
| Aug 3, 2022 | Goldman Sachs | Neutral | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 3, 2026
Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback
NAUT shifts to targeted proteoform assays as broadscale plans falter; Voyager roadmap improves.
SeekingAlpha · Jul 28, 2026
Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call July 28, 2026 8:30 AM EDTCompany ParticipantsSujal Patel - Co-Founder, CEO, President, Secretary...
Benzinga · Jul 28, 2026
Nautilus Biotechnology Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $190.000K
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 8.33 percent increase over losses of $(0.12) per share
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
